Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 19, 2026, 2:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,086 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Alzheimer Disease Clear all
Completed Phase 1 Interventional

TNF-Alpha Inhibition for Treatment of Alzheimer's Disease

NCT00203359
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
etanercept given by perispinal administration
Drug
Lead sponsor
Tobinick, Edward Lewis, M.D.
Other
Eligibility
0 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2006 · Synced Sep 19, 2026, 2:01 PM EDT
Completed Not applicable Interventional Results available

Zolpidem CR and Hospitalized Patients With Dementia

NCT00814502
View directory record Official record
Conditions
Dementia, Alzheimer Disease, Dementia, Vascular, Sleep Disorders, Circadian Dysregulation
Interventions
Zolpidem CR, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 21, 2017 · Synced Sep 19, 2026, 2:01 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION)

NCT02615002
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Piromelatine, Placebo
Drug
Lead sponsor
Neurim Pharmaceuticals Ltd.
Industry
Eligibility
60 Years to 85 Years
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
56
States / cities
Birmingham, Alabama • Tucson, Arizona • Bellflower, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2024 · Synced Sep 19, 2026, 2:01 PM EDT
Recruiting Not applicable Interventional

Remotely-supervised Neuromodulation in PPA

NCT07260253
View directory record Official record
Conditions
Primary Progressive Aphasia(PPA), Progressive Aphasia, Progressive Aphasia in Alzheimer's Disease, Logopenic Progressive Aphasia (LPA), Logopenic Variant Primary Progressive Aphasia, Logopenic Variant of Primary Progressive Aphasia (LPA)
Interventions
Lexical Retrieval Cascade Treatment, Remotely Supervised Transcranial Direct Current Stimulation- Active, Remotely Supervised Transcranial Direct Current Stimulation - Sham
Behavioral · Device
Lead sponsor
Maya Henry
Other
Eligibility
40 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
San Francisco, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 19, 2026, 2:01 PM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

NCT05552157
View directory record Official record
Conditions
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions
Remternetug (SC), Matching Placebo (Remternetug)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2034
U.S. locations
13
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 19, 2026, 2:01 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

NCT01343966
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
MABT5102A, placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
40
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Encino, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Sep 19, 2026, 2:01 PM EDT
Completed Phase 3 Interventional Results available

The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients

NCT00255086
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Memantine, Placebo pill
Drug
Lead sponsor
Stanford University
Other
Eligibility
50 Years to 95 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Sep 19, 2026, 2:01 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Beyond Listening: A Music-based Intervention

NCT04840173
View directory record Official record
Conditions
Alzheimer's Disease (Incl Subtypes), Depressive Symptoms
Interventions
Music
Behavioral
Lead sponsor
MJHS Institute for Innovation in Palliative Care
Other
Eligibility
Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Sep 19, 2026, 2:01 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)

NCT05269394
View directory record Official record
Conditions
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions
E2814, Lecanemab, Matching Placebo (E2814)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
12
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 19, 2026, 2:01 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia

NCT02886494
View directory record Official record
Conditions
Alzheimer's Disease or Vascular Dementia
Interventions
BAC treatment, Matched vehicle
Drug
Lead sponsor
Charsire Biotechnology Corp.
Industry
Eligibility
40 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
10
States / cities
Tempe, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Sep 19, 2026, 2:01 PM EDT
Completed Not applicable Interventional

REmote Assessment and Dynamic Response Intervention

NCT04542109
View directory record Official record
Conditions
Dementia, Alzheimer Disease, Relationship, Marital, Caregiver Stress Syndrome
Interventions
READyR A, READyR B
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
62 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Sep 19, 2026, 2:01 PM EDT
Completed Phase 4 Interventional Results available

A Pilot of Methylphenidate in Mild Cognitive Impairment and Dementia Participants.

NCT03811847
View directory record Official record
Conditions
Alzheimer Dementia
Interventions
Methylphenidate Extended Release Oral Capsule, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
55 Years to 95 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Sep 19, 2026, 2:01 PM EDT
Completed Phase 2 Interventional Results available

Study of Daratumumab in Patients With Mild to Moderate Alzheimer's Disease

NCT04070378
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Daratumumab Injection
Drug
Lead sponsor
Marc L Gordon, MD
Other
Eligibility
55 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 19, 2026, 2:01 PM EDT
Completed Not applicable Interventional

The PREVENTION Trial: Precision Recommendations to Optimize Neurocognition

NCT04082611
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
Data-Driven Clinical Recommendations, Coached Data-Driven Clinical Recommendations
Behavioral
Lead sponsor
Saint John's Cancer Institute
Other
Eligibility
50 Years to 80 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Sep 19, 2026, 2:01 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Exploratory Clinical Study to Assess Safety and Efficacy of Xenon Gas Inhalation to Control Neuroinflammation

NCT06945614
View directory record Official record
Conditions
Healthy Volunteer Study
Interventions
Xenon gas inhalation
Drug
Lead sponsor
General Biophysics LLC
Industry
Eligibility
55 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Sep 19, 2026, 2:01 PM EDT
Completed Not applicable Interventional Results available

Brain Safe: Consumer Intervention to Reduce Exposure to Drugs Linked to Alzheimer's Disease

NCT04121858
View directory record Official record
Conditions
Alzheimer Disease, Dementia
Interventions
Brain Safe App, Attention Control App
Other
Lead sponsor
Indiana University
Other
Eligibility
60 Years and older
Enrollment
706 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 19, 2026, 2:01 PM EDT
Enrolling by invitation Not applicable Interventional

Cholinergic Deep Brain Stimulation for Alzheimer's Disease

NCT05882344
View directory record Official record
Conditions
Alzheimer Disease, Early Onset, Dementia, Alzheimer Disease
Interventions
Device Implantation- Boston Scientific, VERCISE GENUS™ system, DBS Stimulation - Boston Scientific, VERCISE GENUS™ system
Procedure · Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
60 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 19, 2026, 2:01 PM EDT
Completed Phase 3 Interventional Results available

Valproate in Dementia (VALID)

NCT00071721
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Valproate, Placebo
Drug
Lead sponsor
Alzheimer's Disease Cooperative Study (ADCS)
Other
Eligibility
55 Years to 90 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
46
States / cities
Sun City, Arizona • Tucson, Arizona • Irvine, California + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2014 · Synced Sep 19, 2026, 2:01 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - FUTURE Extension

NCT04951284
View directory record Official record
Conditions
Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes), Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
Novoic Limited
Industry
Eligibility
50 Years to 85 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Santa Ana, California
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Sep 19, 2026, 2:01 PM EDT
Completed Not applicable Interventional

Wii-fit for Activity, Balance and Gait in Assisted Living

NCT01000038
View directory record Official record
Conditions
Falls, Alzheimer's Disease
Interventions
Wii-Fit intervention, Walking
Other
Lead sponsor
University of Nebraska
Other
Eligibility
60 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Sep 19, 2026, 2:01 PM EDT
Recruiting Not applicable Interventional

Comparing Structured Retrieval Practice and Reading-Based Education for Dementia Caregivers

NCT07413406
View directory record Official record
Conditions
Dementia, Alzheimer Disease, Caregiver Stress
Interventions
Structured Retrieval Practice, Reading-Based Education
Behavioral
Lead sponsor
Virginia Wesleyan University
Other
Eligibility
50 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Virginia Beach, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 19, 2026, 2:01 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Evaluation and Follow-up of Individuals With Memory Disorder

NCT00001480
View directory record Official record
Conditions
Alzheimer's Disease, Dementia, Healthy, Memory Disorder
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 90 Years
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2007
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 19, 2026, 2:01 PM EDT
Completed Phase 2 Interventional

Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients

NCT01097096
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
CAD106, Placebo, Alum, MF59
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Up to 85 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Costa Mesa, California • Boulder, Colorado • Hollywood, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Sep 19, 2026, 2:01 PM EDT
Withdrawn Phase 2 Interventional

Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease

NCT02667496
View directory record Official record
Conditions
Dementia Alzheimer's Type
Interventions
Sargramostim GZ402664, Placebo, Florbetapir F18
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Sep 19, 2026, 2:01 PM EDT